Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL II China: IDegLira vs IDeg in T2DM
NCT03175120Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c at 26 weeks. Started May 2017; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03175120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175120.